CardioMech AS

CardioMech AS

58 Investors
Minimally Invasive Cardiology
Trondheim, Q8

CardioMech AS is a Norwegian medical device company dedicated to innovating minimally invasive solutions for structural heart disease, particularly degenerative mitral regurgitation (DMR). With a focus on transforming patient care, the company aims to provide effective alternatives to traditional surgery for this common and serious heart condition.

Products & Team

CardioMech Device

Medical DeviceSeed

The CardioMech device functions as an artificial chord for transcatheter mitral valve chordal repair. It is designed to be delivered through a minimally invasive, transfemoral, transseptal approach, allowing for ease of insertion and minimal recovery time.

Value Proposition

The CardioMech device provides a critical solution to patients suffering from mitral regurgitation, offering a less invasive alternative to traditional open-heart surgery, thus reducing recovery times and improving overall patient outcomes.

Pain Points

CardioMech AS addresses the need for less invasive and safer treatment options for mitral regurgitation, particularly for patients who may not be suitable candidates for conventional surgery.

Minimally invasive procedureTransfemoral accessTransseptal navigationReduces/eliminates mitral regurgitationSuitable for both surgical candidates and ineligible patients
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Trondheim, Q8
Primary headquarters

Funding History

Total Raised:
$17.6M
E

Debt Financing Offering

Closed
April 2025
$17.6M
Raised
Progress
100%
Raised
$17.6M
Target
$17.6M
#000104216725000022